Sanofi · 19 hours ago
Senior Scientist – Expert in RNA Biology and Rare Neurodevelopmental Diseases
Cambridge, MA
Full-time
Onsite
Mid, Senior Level
3+ years expSanofi is an innovative global healthcare company dedicated to improving people’s lives through scientific advancements. They are seeking a highly motivated scientist with expertise in RNA biology and neurodevelopmental diseases to lead efforts in discovering and validating RNA-based therapeutic targets and strategies.
Health CareLife SciencePharmaceuticalTherapeutics
Responsibilities
Drive new program initiation by applying RNA biology expertise and RNA associated cutting-edge technologies (in silico prediction of RNA expression/splicing/degradation/export/structure, single nuc/single cell and bulk RNA-seq analysis, splicing analysis from RNA-seq data, in vitro high-throughput splicing assays), for rare neurodevelopmental diseases
Design, develop and conduct in silico, in vitro and in vivo mechanism-of-action, and proof-of-concept studies to validate targets and evaluate therapeutic strategies
Contribute to interdisciplinary research programs in a highly collaborative manner across internal groups and with external partners, with opportunity to grow into a project leadership role
Prepare high-quality analyses, interpretation, documentation, and presentations to support project milestones, publications, patent filings, and potentially regulatory (IND/CTA) filings
Present findings and progress in internal meetings and external venues as appropriate (e.g., publications, conferences, collaboration and governance meetings)
Qualification
Required
Ph.D. or equivalent advanced degree in Molecular Biology, Cellular Biology, In vivo Biology or a related discipline, with 3+ years of relevant experience in a biopharmaceutical or academic research setting
Deep expertise in neurodevelopmental diseases biology and in vivo and in vitro models
Expertise in RNA homeostasis including RNA regulation and processing (e.g., splicing, stability, transport), the roles of regulatory RNAs and translation regulation mechanism
Demonstrated ability to produce high-quality scientific documentation, including experimental protocols, standard operating procedures (SOPs), technical reports, and presentations
Proven track record of meaningful contributions to research programs, evidenced by scientific publications and/or presentations
Preferred
Hands-on experience with disease-relevant in vivo models, including functional and phenotypic assays such as Electroencephalogram (EEG), Paired-Pulse Facilitation assay (PPF), SYNaptic Proximity Ligation Assay (SYNPLA), field excitatory postsynaptic potentials (fEPSPs), synaptic plasticity measurement techniques, behavior, cognitive and motor functional assays
In vitro skills: Proficiency in iPSC culture, imaging microscopy, and high throughput imaging microscopy, in vitro neuronal activity (Microelectrodes array plate), Calcium imaging
Molecular skills: gene expression analysis (qPCR, ddPCR, WB, ELISA/MSD), molecular cloning, vector design, gene editing (e.g., CRISPR)
Experience with discovery, optimization, and development of small molecules and/or oligonucleotides
Familiarity with drug discovery and development processes
Benefits
High-quality healthcare
Prevention and wellness programs
At least 14 weeks’ gender-neutral parental leave
Company
Sanofi
Sanofi is a global biopharma company focused on prescription drugs, vaccines, and treatments for chronic, rare, and infectious diseases.
10001+ employees
H1B Sponsorship
Sanofi has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (101)
2024 (68)
2023 (59)
2022 (78)
2021 (38)
2020 (38)
Funding
Current Stage
Public CompanyTotal Funding
$6.97BKey Investors
Blackstone Life SciencesEvotec
2025-10-28Post Ipo Debt· $3B
2025-06-17Post Ipo Debt· $1.74B
2025-03-05Post Ipo Debt· $1.59B
Leadership Team
Paul Hudson
Chief Executive Officer
Francois-Xavier Roger
Chief Financial Officer
Recent News
2026-01-08
2026-01-08
Company data provided by crunchbase